SG11201909680UA - Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds - Google Patents
Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compoundsInfo
- Publication number
- SG11201909680UA SG11201909680UA SG11201909680UA SG11201909680UA SG 11201909680U A SG11201909680U A SG 11201909680UA SG 11201909680U A SG11201909680U A SG 11201909680UA SG 11201909680U A SG11201909680U A SG 11201909680UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- phenyl
- compounds
- indiana
- eli lilly
- Prior art date
Links
- -1 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit IIl °nolo Oil mo iflo oimIE (10) International Publication Number WO 2018/194885 Al (51) International Patent Classification: C07D 213/82 (2006.01) C07D 239/28 (2006.01) C07D 487/04 (2006.01) (21) International Application Number: PCT/US2018/027005 (22) International Filing Date: 11 April 2018 (11.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17382207.3 18 April 2017 (18.04.2017) EP (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: CIFUENTES-GARCIA, Marta Maria; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). GARCIA-PAREDES, Maria Cristina; c/o Eli Lilly and Company, P.O. Box 6288, Indi- anapolis, Indiana 46206-6288 (US). (74) Agent: TUCKER, Tina M. et al.; c/o Eli Lilly and Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a 1 patent (Rule 4.17(0) pp as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) 71' 1-1 Published: — with international search report (Art. 21(3)) (54) Title: PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS O (57) : The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical com- positions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer. C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382207 | 2017-04-18 | ||
PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909680UA true SG11201909680UA (en) | 2019-11-28 |
Family
ID=58606227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909680U SG11201909680UA (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Country Status (27)
Country | Link |
---|---|
US (2) | US11655214B2 (en) |
EP (2) | EP4039675A1 (en) |
JP (2) | JP7110232B2 (en) |
KR (2) | KR102575246B1 (en) |
CN (2) | CN117510405A (en) |
AU (2) | AU2018255191B2 (en) |
BR (1) | BR112019021867A2 (en) |
CA (1) | CA3060564A1 (en) |
CO (1) | CO2019012767A2 (en) |
CR (1) | CR20190519A (en) |
CY (1) | CY1125150T1 (en) |
DK (1) | DK3612519T3 (en) |
ES (1) | ES2906847T3 (en) |
HR (1) | HRP20220263T1 (en) |
HU (1) | HUE057745T2 (en) |
IL (2) | IL270005B (en) |
LT (1) | LT3612519T (en) |
MX (2) | MX2019012428A (en) |
PH (1) | PH12019502363A1 (en) |
PL (1) | PL3612519T3 (en) |
PT (1) | PT3612519T (en) |
RS (1) | RS62933B1 (en) |
SA (1) | SA519410320B1 (en) |
SG (1) | SG11201909680UA (en) |
SI (1) | SI3612519T1 (en) |
WO (1) | WO2018194885A1 (en) |
ZA (1) | ZA201906811B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117510405A (en) | 2017-04-18 | 2024-02-06 | 礼来公司 | Phenyl-2-hydroxy-acetamido-2-methyl-phenyl compounds |
MX2020009922A (en) | 2018-03-26 | 2020-10-14 | Icahn School Med Mount Sinai | Methods of treating minimal residual cancer. |
WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
AU2020336975A1 (en) | 2019-08-29 | 2022-03-31 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
CN113234029B (en) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | Synthesis method of 2-amino-3, 5-dihalogen pyrazine |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
PT970084E (en) | 1997-03-19 | 2003-10-31 | Abbott Gmbh & Co Kg | PIRROLO¬2,3D | PYRIMIDINES AND THEIR USE AS TYROSIN KINASE INHIBITORS |
TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
KR101139557B1 (en) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
TWI387592B (en) | 2005-08-30 | 2013-03-01 | Novartis Ag | Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis |
WO2007026920A2 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
ES2553390T3 (en) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Method for the detection of truncated intracellular receptors |
US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
BR112012024380A2 (en) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | chemical compounds |
WO2014170706A1 (en) | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
WO2015068767A1 (en) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | Pyrrolo pyrimidine derivative |
JP2017507967A (en) * | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Compounds acting as PERK inhibitors |
WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
US10221181B2 (en) | 2014-11-14 | 2019-03-05 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
CN108026102A (en) * | 2015-07-24 | 2018-05-11 | 蓝印药品公司 | Available for treatment and the compound of the relevant illnesss of KIT and PDGFR |
ES2965081T3 (en) | 2016-07-07 | 2024-04-11 | Daewoong Pharmaceutical Co Ltd | 4-Aminopyrazolo[3,4-d]pyrimidinyl-azabicyclo derivatives and pharmaceutical composition comprising said derivatives |
WO2018015879A1 (en) | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
CN106748989B (en) | 2016-11-14 | 2020-03-17 | 西安交通大学 | Diaryl urea compound with anti-tumor activity and preparation method and application thereof |
EP3573608A1 (en) | 2017-01-30 | 2019-12-04 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
CN117510405A (en) | 2017-04-18 | 2024-02-06 | 礼来公司 | Phenyl-2-hydroxy-acetamido-2-methyl-phenyl compounds |
JP7304855B2 (en) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | Novel imidazopyrimidine compounds and uses thereof |
EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
MX2020009922A (en) | 2018-03-26 | 2020-10-14 | Icahn School Med Mount Sinai | Methods of treating minimal residual cancer. |
CN112384283B (en) | 2018-07-06 | 2023-08-15 | 吉利德科学公司 | Therapeutic heterocyclic compounds |
WO2020070053A1 (en) | 2018-10-01 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/en active Pending
- 2018-04-11 MX MX2019012428A patent/MX2019012428A/en unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/en active Active
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/en active IP Right Grant
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/en unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/en unknown
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/en active Active
- 2018-04-11 EP EP21211015.9A patent/EP4039675A1/en active Pending
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/en unknown
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 CR CR20190519A patent/CR20190519A/en unknown
- 2018-04-11 PL PL18718570T patent/PL3612519T3/en unknown
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 ES ES18718570T patent/ES2906847T3/en active Active
- 2018-04-11 RS RS20220154A patent/RS62933B1/en unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/en unknown
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/en active
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/en not_active Application Discontinuation
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/en unknown
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 CA CA3060564A patent/CA3060564A1/en active Pending
- 2018-04-11 PT PT187185707T patent/PT3612519T/en unknown
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 PH PH12019502363A patent/PH12019502363A1/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/en unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/en unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/en unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/en active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US20230373922A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201900689RA (en) | Compounds and compositions and uses thereof | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |